Prevalence of RT-qPCR-detected SARS-CoV-2 infection at schools: First results from the Austrian School-SARS-CoV-2 prospective cohort study.
Journal
The Lancet regional health. Europe
ISSN: 2666-7762
Titre abrégé: Lancet Reg Health Eur
Pays: England
ID NLM: 101777707
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
entrez:
16
8
2021
pubmed:
17
8
2021
medline:
17
8
2021
Statut:
ppublish
Résumé
The role of schools in the SARS-CoV-2 pandemic is much debated. We aimed to quantify reliably the prevalence of SARS-CoV-2 infections at schools detected with reverse-transcription quantitative polymerase-chain-reaction (RT-qPCR). This nationwide prospective cohort study monitors a representative sample of pupils (grade 1-8) and teachers at Austrian schools throughout the school year 2020/2021. We repeatedly test participants for SARS-CoV-2 infection using a gargling solution and RT-qPCR. We herein report on the first two rounds of examinations. We used mixed-effects logistic regression to estimate odds ratios and robust 95% confidence intervals (95% CI). We analysed data on 10,734 participants from 245 schools (9465 pupils, 1269 teachers). Prevalence of SARS-CoV-2 infection increased from 0·39% at round 1 (95% CI 028-0·55%, 28 September-22 October 2020) to 1·39% at round 2 (95% CI 1·04-1·85%, 10-16 November). Odds ratios for SARS-CoV-2 infection were 2·26 (95% CI 1·25-4·12, This monitoring study in Austrian schools revealed SARS-CoV-2 infection in 0·39%-1·39% of participants and identified associations of regional community incidence and social deprivation with higher prevalence. BMBWF Austria.
Sections du résumé
BACKGROUND
BACKGROUND
The role of schools in the SARS-CoV-2 pandemic is much debated. We aimed to quantify reliably the prevalence of SARS-CoV-2 infections at schools detected with reverse-transcription quantitative polymerase-chain-reaction (RT-qPCR).
METHODS
METHODS
This nationwide prospective cohort study monitors a representative sample of pupils (grade 1-8) and teachers at Austrian schools throughout the school year 2020/2021. We repeatedly test participants for SARS-CoV-2 infection using a gargling solution and RT-qPCR. We herein report on the first two rounds of examinations. We used mixed-effects logistic regression to estimate odds ratios and robust 95% confidence intervals (95% CI).
FINDINGS
RESULTS
We analysed data on 10,734 participants from 245 schools (9465 pupils, 1269 teachers). Prevalence of SARS-CoV-2 infection increased from 0·39% at round 1 (95% CI 028-0·55%, 28 September-22 October 2020) to 1·39% at round 2 (95% CI 1·04-1·85%, 10-16 November). Odds ratios for SARS-CoV-2 infection were 2·26 (95% CI 1·25-4·12,
INTERPRETATION
CONCLUSIONS
This monitoring study in Austrian schools revealed SARS-CoV-2 infection in 0·39%-1·39% of participants and identified associations of regional community incidence and social deprivation with higher prevalence.
FUNDING
BACKGROUND
BMBWF Austria.
Identifiants
pubmed: 34396360
doi: 10.1016/j.lanepe.2021.100086
pii: S2666-7762(21)00063-6
pmc: PMC8350968
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100086Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in relation to this study.
Références
J Clin Microbiol. 2012 Mar;50(3):891-6
pubmed: 22205820
Med J Aust. 2020 Nov;213(10):444-446.e1
pubmed: 33099775
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Science. 2020 Sep 4;369(6508):1146
pubmed: 32883837
N Engl J Med. 2020 Sep 3;383(10):981-985
pubmed: 32726550
Can J Public Health. 2021 Aug;112(4):566-575
pubmed: 34047966
MMWR Morb Mortal Wkly Rep. 2020 Aug 07;69(31):1023-1025
pubmed: 32759921
Emerg Infect Dis. 2020 Oct;26(10):2465-2468
pubmed: 32673193
J Virol Methods. 2017 Oct;248:83-86
pubmed: 28633963
Lancet Infect Dis. 2021 Feb;21(2):193-202
pubmed: 33729915
Eur J Public Health. 2020 Dec 11;30(6):1176-1180
pubmed: 32818263
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33514627
Euro Surveill. 2020 Sep;25(38):
pubmed: 32975186
Infect Control Hosp Epidemiol. 2021 Feb;42(2):248-249
pubmed: 32389132
Commun Med (Lond). 2021;1(1):4
pubmed: 34870284
MMWR Morb Mortal Wkly Rep. 2020 Nov 06;69(44):1631-1634
pubmed: 33151916
Lancet Infect Dis. 2021 Mar;21(3):344-353
pubmed: 33306981
JAMA. 2020 Jun 16;323(23):2427-2429
pubmed: 32432657
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
JAMA Pediatr. 2020 Sep 1;174(9):902-903
pubmed: 32745201
Biometrics. 2000 Jun;56(2):645-6
pubmed: 10877330
Nat Immunol. 2021 Jan;22(1):25-31
pubmed: 33154590
Clin Infect Dis. 2020 Jul 28;71(15):893-894
pubmed: 32241023
Euro Surveill. 2020 May;25(21):
pubmed: 32489179
Int J Epidemiol. 2022 Jan 6;50(6):1795-1803
pubmed: 34999848
Clin Infect Dis. 2020 Nov 5;71(8):1980-1981
pubmed: 32271374
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
Lancet Child Adolesc Health. 2020 Nov;4(11):807-816
pubmed: 32758454
BMJ. 2020 Jun 8;369:m2149
pubmed: 32513666
Clin Infect Dis. 2021 May 18;72(10):e604-e607
pubmed: 32918071
Clin Infect Dis. 2020 Nov 19;71(16):2073-2078
pubmed: 32358960
Emerg Infect Dis. 2020 Oct;26(10):2494-2497
pubmed: 32603290